close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biocorrx Inc (OP:BICX)

0.4000 -0.0498 (-11.07%)
Streaming Delayed Price Updated: 1:09 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 400
Open 0.4600
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.4498
Today's Range 0.4000 - 0.4600
52wk Range 0.2120 - 1.450
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioCorRx Reports 3,985% Revenue Growth to $313K in the First Half of 2025 Driven by LUCEMYRA(R) (lofexidine) Sales
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Death
BioCorRx Reports 3,985% Revenue Growth to $313K in the First Half of 2025 Driven by LUCEMYRA(R) (lofexidine) Sales
Via TheNewswire.com
Topics Death

Performance

YTD
-2.4%
-2.4%
1 Month
+34.7%
+34.7%
3 Month
+5.3%
+5.3%
6 Month
+39.6%
+39.6%
1 Year
-15.9%
-15.9%

More News

Read More
BioCorRx Reports Business Update for the First Quarter of 2025
Via NewMediaWire
Topics Death
BioCorRx Reports Business Update for the First Quarter of 2025
Via TheNewswire.com
Topics Death
BioCorRx Pharmaceuticals Inc. Announces That it has Acquired LUCEMYRA(R) (lofexidine), an FDA-Approved Opioid Withdrawal Medication, From USWM, LLC
Via NewMediaWire
BioCorRx Pharmaceuticals Inc. Announces That it has Acquired LUCEMYRA(R) (lofexidine), an FDA-Approved Opioid Withdrawal Medication, From USWM, LLC
Via TheNewswire.com
BioCorRx Reports Business Update for the Second Quarter of 2024
Via NewMediaWire
Topics Intellectual Property
BioCorRx Reports Business Update for the First Quarter of 2024
Via NewMediaWire
Topics Death Intellectual Property
BioCorRx Reports Business Update for the First Quarter of 2024
Via TheNewswire.com
Topics Death Intellectual Property
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
Via NewMediaWire
Topics Intellectual Property
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
Via TheNewswire.com
Topics Intellectual Property
BioCorRx Reports Business Update for 2023
Via NewMediaWire
Topics Death
BioCorRx Reports Business Update for 2023
Via TheNewswire.com
Topics Death
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
Via NewMediaWire
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
Via TheNewswire.com
Topics Death
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
Via NewMediaWire
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
Via TheNewswire.com
Collective Audience And 3 Other Stocks Under $1 Insiders Are Buying
Via Benzinga
Topics Stocks
BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President
Via NewMediaWire
BioCorRx Reports Business Update for the Third Quarter of 2023
Via NewMediaWire
Topics Death
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder
Via NewMediaWire
BioCorRx Reports Business Update for the Second Quarter of 2023
Via NewMediaWire
BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder
Via NewMediaWire
Topics Death
Rezolute And 2 Other Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
BioCorRx Provides Business Update for the First Quarter of 2023
Via NewMediaWire

Frequently Asked Questions

Is Biocorrx Inc publicly traded?
Yes, Biocorrx Inc is publicly traded.
What exchange does Biocorrx Inc trade on?
Biocorrx Inc trades on the OTC Traded
What is the ticker symbol for Biocorrx Inc?
The ticker symbol for Biocorrx Inc is BICX on the OTC Traded
What is the current price of Biocorrx Inc?
The current price of Biocorrx Inc is 0.4000
When was Biocorrx Inc last traded?
The last trade of Biocorrx Inc was at 10/17/25 01:09 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today